Richter Signs Term Sheet With Mithra for Sales of Donesta
Hungarian pharmaceutical company Gedeon Richter on Tuesday said it signed a binding term sheet with Belgian peer Mithra Pharmaceuticals on the commercialization of Donesta, an estetrol-based product candidate for hormone replacement therapy in postmenopausal women, according to a report by state news wire MTI.
The parties intend to finalize their partnership, which extends to Europe, including Russia and the CIS, Latin America, Australia, and New Zealand, in Q1 2023.
Under the terms of the agreement, Mithra is eligible to receive upfront payments totaling EUR 55m as well as EUR 15m in additional milestone payments subject to regulatory achievements and "tiered low double-digit" royalties depending on net sales.
Mithra announced positive top-line results from Donesta phase 3 studies in menopausal women in January 2022.
ÁKK Sells HUF 82.5 bln of Bonds at Auction, Above Plan
EC Puts Hungary 2024 GDP Growth at 2.4%
HU-rizon Program: HUF 8 bln Funding for International Resear...
Marcelito Pomoy to Perform in Budapest Next Week
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
